You are here

Home » Content

Kronik Böbrek Yetmezlikli Hastalarda Sekonder Hiperparatrodizm ve Oksidatif Stress Arasındaki İlişkinin Araştırılması

The Investigation of Relationship Between Secondary Hyperparathyroidism and Oxidative Stress in Patients with Chronic Kidney Disease

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2009

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
OBJECTIVES: Our aim was to investigate the changes of the oxidant and antioxidant systems in chronic kidney disease patients who had increased parathyroid hormone (PTH) levels in the present study. PATIENTS and METHODS: A total of fifty hemodialysis patients were divided into two equal groups based on the PTH levels; > 300 pg/mL (Group 1) and < 300 pg/mL (Group 2). A total 20 healthy subjects were included in the study as the control group (Group 3). The measurement of malondialdehyde (MDA), advanced protein oxidation products level (AOPP), ascorbic acid (AA) levels, and activities of myeloperoxidase (MPO) and catalase (CAT) were performed by colorimetric methods. PTH measurement was also performed by chemiluminescent method. RESULTS: As compared with control group, MDA level was significantly higher in Groups 1 and 2 (p<0.05), and the AOPP level was higher in Group 2 (p<0.05) only. The MPO activity was significantly lower in Group 1 as compared to the control group (p<0.05). The CAT activity and AA levels were significantly lower in Groups 1 and 2 than in the control group (p<0.05). CONCLUSIONS: This study has shown that patients with chronic kidney disease are characterized by increased oxidative stress and decreased antioxidant defense systems. However, increased PTH levels did not have an additional effect on the oxidant and antioxidant mechanisms in these patients.
Bookmark/Search this post with
Abstract (Original Language): 
AMAÇ: Bu çalışmada, paratroid hormon (PTH) seviyesi yüksek kronik böbrek yetmezlikli hastalarda, oksidan ve antioksidan sistemlerdeki değişikliklerin araştırılması amaçlanmıştır. GEREÇ ve YÖNTEM: Toplam 50 hemodiyaliz hastası PTH düzeyleri esas alınarak iki eşit gruba bölündü; PTH düzeyi > 300 pg/mL (Grup 1) ve < 300 pg/mL (Grup 2). Yirmi sağlıklı kişi kontrol grubu (Grup 3) olarak çalışmaya katılmıştır. Malondialdehit (MDA), ilerlemiş protein oksidasyon ürünü (AOPP), askorbik asit (AA) düzeyleri ve myeloperoksidaz (MPO) ve katalaz (KAT) aktivitesi ölçümleri kolorimetrik yöntemle gerçekleştirilmiştir. PTH ölçümü ise kemiluminens yöntemle gerçekleştirilmiştir. BULGULAR: Kontrol grubuyla karşılaştırıldığında, MDA düzeyi grup 1 ve 2’de, AOPP düzeyi ise sadece grup 2’de anlamlı artış göstermiştir (p<0.05). MPO aktivitesi ise grup 1’de kontrol grubuna göre anlamlı azalma göstermiştir (p<0,05). KAT aktivitesi ve AA düzeyleri, kontrol grubuna göre, hem grup 1 hem de grup 2’de anlamlı olarak azalmıştır (p<0,05). SONUÇ: Bu çalışma, kronik böbrek yetmezlikli hastaların artmış oksidatif stres ve azalmış antioksidan savunma sistemiyle karakterize olduğunu göstermiştir. Bununla birlikte, PTH yüksekliğinin bu hastalarda oksidan ve antioksidan mekanizma üzerinde herhangi bir etkiye sahip olmadığını göstermiştir.
FULL TEXT (PDF): 
PDF icon arastrmx_172977_18_pp_69-75.pdf
  • 2
69-75
  • Turkish

REFERENCES

References: 

1. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH:
Longitudinal follow-up and outcomes among a population with
chronic kidney disease in a large managed care organization. Arch
Intern Med 2004; 164:659–663
2. Himmelfarb J, Hakim RM: Oxidative stress in uremia. Curr Opin
Nephrol Hypertens 2003;12: 593–598
3. Wu CC, Chen JS, Wu WM, Liao TN, Chu P, Lin SH, Chuang
CH, Lin YF: Myeloperoxidase serves as a marker of oxidative
stress during single hemodialysis session using two different
biocompatible dialysis membranes, Nephrol Dial Transplant 2005;
20:1134-1139
4. Miyata T, Kurokawa K, van Ypersele de Strihou C: Relevance of
oxidative and carbonyl stress to long-term uremic complications.
Kidney Int 2000; 76:120–125
5. Floccari F, Aloisi C, Crasci E, Sofi T, Campo S, Tripodo D, Criseo
M, Frisina N, Buemi M: Oxidative stress and uremia. Med Res Rev
2005; 25(4):473-486
6. Massy ZA, Nguyen-Khoa T. Oxidative stress and chronic renal
failure: Markers and management. J Nephrol 2002;15: 336–341
7. Witko-Sarsat V, Friedlander M, Capeiller-Blandin C, Nguyen-
Khoa T, Nguyen AT, Zingraff J, Jungers P, Descamps-Latscha B:
Advanced oxidized protein products as a novel marker of oxidative
stress in uremia. Kidney Int 1996; 49:1304–1313
8. Kalousova M, Zima T, Tesar V, Dusilova-Sulkova S, Skrha J:
Advanced glycoxidation end products in chronic diseases-clinical
chemistry and genetic background. Mutat Res. 2005; 579: 37-46
9. Hampton MB, Kettle AJ, Winterbourn CC. Inside the neutrophil
phagosome: Oxidants, myeloperoxidase and bacterial killing.
Blood 1998; 92: 3007–3017
10. Brennan ML, Hazen SL: Emerging role of myeloperoxidase and
oxidant stress markers in cardiovascular risk assessment. Curr Opin
Lipidol 2003;14: 353–359
NOYAN: The Investigation of Relationship Between
Secondary Hyperparathyroidism and Oxidative
Stress in Patients with Chronic Kidney Disease
Cilt/Vol. 18, No, 2, 2009 Sayfa/Page 69-75
74
Türk Nefroloji Diyaliz ve Transplantasyon Dergisi
Turkish Nephrology, Dialysis and Transplantation Journal
75
11. Capeillere- Blandin C, Gausson V, Nguguyen AT, Descamps-
Latscha B, Grueke T, Witko-Sarsat V: Respective role of uraemic
toxins and myeloperoxidase in the uraemic state. Nephrol Dial
Transplant 2006; 21: 1555–1563
12. Bro S, Olgaard K: Effects of excess PTH on nonclassical target
organs. Am J Kidney Dis 1997; 30: 606–620.
13. Savica V, Calò LA, Monardo P, Santoro D, Mallamace A,
Muraca U, Bellinghieri G: Salivary phosphorus and phosphate
content of beverages: Implications for the treatment of uremic
hyperphosphatemia. J Ren Nutr 2009; 19: 69-72
14. Wasowicz W, Neve J, Peretz A: Optimized steps in fluorometric
determination of thiobarbituric acid-reactive substances in serum:
importance of extraction ph and influence of sample preservation
and storage. Clin Chem 1993; 39: 2522-2526
15. Bradley PP, Priebat DA, Christensen RD, Rothstein G: Measurement
of cutaneous inflammation: Estimation of neutrophil content with
an enzyme marker. J Invest Dermatol 1982; 78: 206-209
16. Goth L: A simple method for determination of serum catalase
activity, and revision of reference range. Clin Chim Acta 1991; 196:
143-152
17. McCormick DB, Greene HL: Vitamins. In: Burtis CA, Ashwood
ER, editors. Tietz Textbook of Clinical Chemistry. 3rd ed. W.B
Saunders Company, Philadelphia 1999. 1023
18. Jackson P, Loughrey CM, Lightbody JH, McNamee PT, Young
IS: Effect of hemodialysis on total antioxidant capacity and serum
antioxidants in patients with chronic renal failure. Clin Chem 1995;
41: 1135–1138
19. Becker BN, Himmelefarb J, Henrich W, Hakim RM: Reassessing the
cardiac risk profile in chronic hemodialysis patients: A hypothesis
on role of oxidant stress and other non-traditional cardiac risk
factors. J Am Soc Nephrol 1997; 8: 475–486
20. Rashid G, Bernheim J, Gren J, Benchetrit S: Parathyroid hormone
stimulates endothelial expression of atherosclerotic parameters
through protein kinase pathways. Am J Physiol Renal Physiol
2007; 292: 1215-1218
21. Roman RJ, Maier KG, Sun CW, Harder DR, Alonso- Galicia M:
Renal and cardiovascular actions of 20-hydroxyeicosatetraenoic
acid and epoxyeicosatrienoic acids. Clin Exp Pharmacol Physiol
1989; 27: 855–865
22. Malle E, Buch T, Grone HJ. Myeloperoxidase in kidney disease.
Kidney Int 2003; 64: 1956-1967
23. Ozden M, Maral H, Akaydin D, Cetinalp P, Kalender B: Erytrocyte
glutathione peroxidase activity plasma malondialdehyde and
erythrocyte glutathione levels in hemodialysis and CAPD patients.
Clin Biochem 2002; 35: 269-273
24. Holvoet P, Donck J, Landeloos M, Brouwers E, Luijtens K, Arnout
J, Lesaffre E, Vanrenterghem Y, Collen D: Correlation between
oxidized low density lipoproteins and von Willebrand factor in
chronic renal failure. Tromb Haemost 1996; 76: 663–669
25. Wratten ML, Sereni L, Tetta C: Hemolipodialysis attenuates
oxidative stress and removes hydrophobic toxins. Artif Organs
2000; 24: 685–690
26. Witko-Sarsat V, Friedlander M, Nguyen Khoa T, Capeiller-Blandin
C, Nguyen AT, Cantelous S, Dayer JM, Jungers P, Drueke T,
Descamps-Latscha B: Advanced oxidized protein products as novel
mediators of inflammation and monocyte activation in chronic renal
failure. J Immunol 1998; 161: 2524–3252
27. Himmelfarb J, McMonagle E, McMenamin E: Plasma protein thiol
oxidation and carbonyl formation in chronic renal failure. Kidney
Int 2000; 58: 2571-2578
28. Capeillere- Blandin C, Gausson V, Nguyen AT, Descamps-Latscha
B, Grueke T, Witko-Sarsat V: Respective role of uraemic toxins
and myeloperoxidase in the uraemic state. Nephrol Dial Transplant
2006; 21:1555-1563
29. Witko-Sarsat V, Gausson V, Nguyen AT, Touam M, Drueke T,
Santangelo F, Descamps-Latscha B: AOPP-induced activation of
human neutrophil and monocyte oxidative metabolism: a potential
target for N-acetyl-cysteine treatment in dialysis patients. Kidney
Int 2003; 64: 82–91
30. Wu CC, Chen JS, Wu WM, Liao TN, Chu P, Lin SH, Chuang
CH, Lin YF: Myeloperoxidase serves as a marker of oxidative
stress during single hemodialysis session using two different
biocompatible dialysis membranes. Nephrol Dial Transplant 2005;
20: 1134–1139
31. Krieter DH, Lemke HD, Wanner C: Myeloperoxidase serves as a
marker of oxidative stress during single hemodialysis session using
two different biocompatible dialysis membranes. Nephrol Dial
Transplant 2006; 21: 546
32. Léculier C, Couprie N, Adeleine P, Leitienne P, Francina A, Richard
M: The effects of high molecular weight- and low molecular
weight-heparins on superoxide ion production and degranulation
by human polymorphonuclear leukocytes. Thromb Res. 1993; 69:
519-531
33. Leitienne P, Fouque D, Rigal D, Adeleine P, Trzeciak MC,
Laville M: Heparins and blood polymorphonuclear stimulation
in haemodialysis: an expansion of the biocompatibility concept.
Nephrol Dial Transplant 2000; 15:1631-1637
34. Giray B, Kan E, Bali M, Hincal F, Basaran N. The effect of
vitamin E supplementation on oxidant enzyme activities and lipid
peroxidation levels in hemodialysis patients. Clin Chim Acta 2003;
338: 91-8
35. González -Diez B, Cavia M, Torres G, Abaigar P, Muñiz P:
Effect of a hemodiafiltration session with on line regeneration
of the ultrafiltrate on oxidative stress. Comparative study with
conventional hemodialysis with polysulfone. Blood Puriff 2008;
26: 505-510
36. Eiselt J, Racek J, Opatmy K Jr, Trefil L, Stehlik P: The effect of
intravenous iron on oxidative stress in hemodialysis patients at
various levels of vitamin C. Blood Purif 2006; 24: 531-537
37. Mydlik M, Derzsiova K, Racz O, Sipulova A, Loyasova E:
Antioxidant therapy by oral vitamin E and vitamin E-coated
dialyzer in CAPD and hemodialysis patients. Prague Med Rep
2006; 107: 354-364
38. Paul J-L, Sall ND, Soni T, Poignet JL, Lindenbaum A, Man NK,
Moatti N, Raichvarg D: Lipid peroxidation abnormalities in
hemodialyzed patients. Nephron 1993; 64:106–109
39. Asayama K, Shiki Y, Ito H, Hasegawa O, Miyao A, Hayashibe
H, Dobashi K, Kato K: Antioxidant enzymes and lipoperoxide in
blood in uremic children and adolescents. Free Radic Biol Med
1990; 9: 105 –109
40. Yılmaz FM, Çelebi N, Duranay M, Yılmaz H, Kazan N, Yücel D:
The effect of hemodialysis on the levels of vitamin C, E and A in a
group of chronic renal failure patients. Turk J Biochem 2003; 28:
35-39

Thank you for copying data from http://www.arastirmax.com